News

U.S. Stock Market Update

1 Mins read

As the opening bell approaches for U.S. stock markets, Roivant Sciences Ltd. (ROIV) is showing an impressive 14.1% increase in pre-market trading, while Liberty Media Corp. Series A Sirius XM (LSXMA) is up by 10.9%.

Other notable gainers in pre-market trading include Liberty Media Corp. Series C SiriusXM (LSXMK), DraftKings Inc. Cl A (DKNG), and Garmin Ltd. (GRMN), all experiencing gains of at least 3%. However, NetApp Inc. (NTAP) and Sirius XM Holdings Inc. (SIRI) are facing declines, dropping by 5.6% and 4.2% respectively.

Looking at the futures, the S&P 500 futures are down 0.45%, while Dow Jones Industrial Average futures are falling 0.37%. The Cboe Volatility Index futures are down 1.09%.

In commodities news, Brent crude oil futures show a decrease of 0.63%, and gold futures are down by 0.28%. Bitcoin also slipped by 0.35%, currently priced at $26,223.

Furthermore, the 10-Year Treasury yield has dropped to 4.495%.

During the previous regular trading session, the S&P 500 and the Dow recorded gains of 0.40% and 0.13% respectively. However, stocks in Asia faced a decline overnight, with Japan’s NIKKEI 225 Index down by 1.11% and China’s Shanghai Composite Index falling by 0.43%.

In afternoon trading, European stocks are showing mixed results, as the STOXX Europe 600 Index is down 0.49%, while the FTSE 100 Index has climbed by 0.10% since the previous close.

Stay tuned as U.S. stock markets open for trading at 9:30 a.m. ET.

Related posts
News

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…
News

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…
News

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

40 − 31 =